“Semaglutide for $25” refers to Novo Nordisk’s manufacturer savings cards for its brand semaglutide products — the Ozempic, Wegovy, and Rybelsus Savings Cards. With eligible commercial (employer or marketplace) insurance that covers the drug, the card can bring your copay to as little as $25/month (as low as $0 for Wegovy, $10 for Rybelsus). Federal rules exclude Medicare, Medicaid, VA, and TRICARE.
There is no generic semaglutide, so if you are uninsured the $25 card does not apply. The cheapest cash routes are the oral Wegovy pill from about $149/month or NovoCare self-pay injectable Wegovy around $349/month for maintenance doses ($199/month introductory); compounded semaglutide via licensed telehealth can be lower (from about $69/month) but is not FDA-approved as a finished drug. Estimates as of July 2026.